Clinical trials · New York, NY
Interstitial Lung Disease clinical trials in New York
We’re tracking 23 recruiting interstitial lung disease studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
New York, New YorkAges 18 years+ - NCT03295279Enrolling by invitation
Use of chest CT scans from WTC Health Plan participants
This study creates a research archive of chest CT scan images from people enrolled in the World Trade Center (WTC) Health Plan program at Mount Sinai. It may help doctors and researchers better understand and track chest health over time using existing scan images.
New York, New YorkAges 18 years+ - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
New York, New YorkAges 40 years+ - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
New York, New YorkAges 18 years+ - NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
New York, New YorkAges 18–80 - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
New York, New YorkAges 40 years+ - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
New York, New YorkAges 18 years+ - NCT07179380RecruitingPhase 3
A study of an inhaled drug for lung disease with high blood pressure
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
New York, New YorkAges 18 years+ - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
New York, New YorkAges 18 years+ - NCT06572384RecruitingPhase 3
Belimumab for lung scarring in autoimmune disease
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
New York, New YorkAges 18 years+ - NCT06806592RecruitingPhase 3
Testing nerandomilast for lung scarring from rheumatic disease
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
New York, New YorkAges 18 years+ - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
New York, New YorkAges 18 years+ - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New York, New YorkAges 18–75 - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
New York, New YorkAges 18 years+ - NCT06855329Recruiting
Studying progressive lung scarring (non-IPF)
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
New York, New YorkAges 18–80 - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
New York, New YorkAges 21 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
New York, New YorkAges 18 years+ - NCT05854563Recruiting
Study using collected cough samples to learn about lung disease
This trial looks at “cough capture” samples to better understand what is happening in the lungs. You might be eligible if you’re having a bronchoscopy for medical reasons and don’t already have lung cancer.
The Bronx, New YorkAges 21 years+ - NCT04930289Enrolling by invitation
Lung transplant registry for better donor lung preservation
This study builds a worldwide database to track and improve how donor lungs are preserved before transplant. Your information may help doctors choose and manage donor lungs more effectively.
The Bronx, New YorkAges Any age - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Hackensack, New JerseyAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
East Brunswick, New JerseyAges 18 years+ - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
East Brunswick, New JerseyAges 18 years+
Hear when a new Interstitial Lung Disease trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Interstitial Lung Disease trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting interstitial lung disease studies listed above.
- Weill Cornell Medicine · 7 studies
- Northwell Health · 5 studies
- NYU Langone Health · 4 studies
- Astera Cancer Care · 2 studies
- Columbia University Irving Medical Center · 2 studies
- GSK Investigational Site · 2 studies
- Memorial Sloan Kettering Cancer Center · 2 studies
- Montefiore Medical Center · 2 studies
What taking part in a interstitial lung disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting interstitial lung disease studies in New York.
Common questions
- Are there interstitial lung disease clinical trials near New York?
- Yes. We're currently tracking 23 recruiting interstitial lung disease studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a interstitial lung disease study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New interstitial lung disease studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.